Edition:
India

Bavarian Nordic A/S (BAVA.CO)

BAVA.CO on Copenhagen Stock Exchange

245.50DKK
9:29pm IST
Change (% chg)

kr.13.50 (+5.82%)
Prev Close
kr.232.00
Open
kr.234.00
Day's High
kr.248.20
Day's Low
kr.232.30
Volume
537,386
Avg. Vol
317,644
52-wk High
kr.444.00
52-wk Low
kr.183.00

Select another date:

Fri, Jan 19 2018

BRIEF-Bavarian Nordic Initiates Clinical Trial With Novel Cancer Immunotherapy

* REG-BAVARIAN NORDIC ANNOUNCES INITIATION OF CLINICAL TRIAL WITH NOVEL CANCER IMMUNOTHERAPY TARGETING BRACHYURY IN CANCER METASTASIS

Merkel's allies, further defying SPD, seek cuts to tax and asylum seeker benefits

BERLIN Germany's Bavarian conservatives are pressing for corporate tax cuts and cuts to welfare payments for asylum seekers, which could complicate talks with the Social Democrats (SPD) on forming a new government.

BRIEF-Bavarian Nordic Q3 EBIT at DKK 432 million

* Q3 EBIT DKK 432.0 ‍​ MILLION VERSUS LOSS DKK 124.8 MILLION YEAR AGO

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

SGS and Bavarian Nordic developing challenge strain to combat respiratory virus​

ZURICH, Oct 12 SGS and Bavarian Nordic are teaming up to develop a virus challenge strain to combat a common respiratory illness.

BRIEF-Bavarian Nordic wins big smallpox vaccine order for U.S. government

* SECURES CONTRACT AWARD FOR SUPPLY OF FREEZE-DRIED IMVAMUNE SMALLPOX VACCINE TO THE U.S. GOVERNMENT

BRIEF-Bavarian Nordic provides update on its RSV vaccine

* REG-BAVARIAN NORDIC PROVIDES UPDATE ON ITS UNIVERSAL RSV VACCINE

BRIEF-Bavarian Nordic says independent Data Monitoring Committee determined continuation of Phase 3 prospect study of Prostvac is futile

* Independent Data Monitoring Committee recommends discontinuation of Bavarian Nordic's Phase 3 study of Prostvac in metastatic prostate cancer

Bavarian Nordic says first milestone payment under J&J deal could be in 2019

COPENHAGEN Danish biotech company Bavarian Nordic expects to get its first milestone payment under a deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.

UPDATE 1-Bavarian Nordic says first milestone payment under J&J deal could be in 2019

* But may take on some risk in respiratory diseases (adds detail on RSV, Prostvac and partnerships)

Select another date: